Trials / Completed
CompletedNCT03645915
GLUT1: A Novel Tool re fl Ecting Proliferative Activity of Lung Neuroendocrine Tumors
GLUT1: A Novel Tool Reflecting Proliferative Activity of Lung Neuroendocrine Tumors
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 36 (actual)
- Sponsor
- Centre Hospitalier Universitaire, Amiens · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Lung neuroendocrine tumor (LNT) represents approximately 20% of all lung cancers. The classification of LNT relies upon morphology. Recently, in the World Health Organization (WHO) classification, Ki-67 rate has been proposed for classi fication. It is, however, known that Ki-67 count has a poor interlaboratory reproducibly. For that reason, our team has looked for a new biomarker. GLUT1 protein a facilitative glucose transporter protein which has ubiquitous expression in mammalian. GLUT1 is overexpressed in many human cancers. But, no study has evaluated the GLUT1 staining as an aid diagnosis in LNT. The team have assessed the GLUT1 immunohistochemical staining in 36 LNT and to assess its diagnostic value.
Detailed description
The (LNT) Lung neuroendocrine tumor represents approximately 20% of all lung cancers. The classification of LNT relies upon morphology. Recently, in the World Health Organization (WHO) classification, Ki-67 rate has been proposed for classi fication. It is, however, known that Ki-67 count has a poor interlaboratory reproducibly. For that reason, our team has looked for a new biomarker. GLUT1 protein a facilitative glucose transporter protein which has ubiquitous expression in mammalian. GLUT1 is overexpressed in many human cancers. But, no study has evaluated the GLUT1 staining as an aid diagnosis in LNT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Immunohistochemistry | Immunohistochemistry of Glut1 expression was performed in these 36 cases of neuroendocrine tumor. |
Timeline
- Start date
- 2014-01-01
- Primary completion
- 2016-11-13
- Completion
- 2016-11-13
- First posted
- 2018-08-24
- Last updated
- 2018-08-24
Source: ClinicalTrials.gov record NCT03645915. Inclusion in this directory is not an endorsement.